Last year I heard from several sources that there somewhere between 3-5 unpublished manuscripts reporting the use of CRISPR gene targeting in human embryos being shopped around at various journals in addition to the one that had been published. Since that time we’ve seen a grand total of one additional paper reporting on CRISPR of human […]
Where are all the new CRISPR human embryo papers? Read More »
Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can
In Depth Report from April 29th Paris Human Gene Edit Meeting Read More »
Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of
Paris human gene editing workshop summary Read More »
With the approval today of the use of CRISPR in human embryos, the UK continues its recent trend toward a more permissive regulatory policy on human genetic modification. There are both risks and scientific benefits that come along with this trend. Last year the UK approved an experimental technology with the goal of preventing the
CRISPR embryo OK signals ongoing liberal UK trend on human modification Read More »
I just got back from a historic summit on human genetic modification in Washington, D.C. New genetic modification technology, termed CRISPR-Cas9, has both made genetic modification a relatively simple matter for scientists and human genetic modification much more likely in the near future. Heritable human genetic modification could prevent some rare genetic diseases so there
Now we have an interesting panel starting on questions of governance on human gene editing. This will focus on institutional and national levels of governance. Pilar N. Ossorio, University of Wisconsin, Madison, and Morgridge Institute for Research, is introducing the panel. Key question: how should emerging technologies being governed? Jonathan Kimmelman, from McGill, was the first
Live Blogging #GeneEditSummit Day 2 Post #1: Governance of human gene editing Read More »
I’ve written extensively about the potential use of CRISPR in humans, including in particular in the germline where it would lead to heritable genetic modifications. Research using CRISPR in human embryos strictly for research purposes (not reproduction) is proceeding and in the case of non-viable embryos, such work has already been published (e.g. here), but
Human CRISPR TED talk Read More »
Note that this poll is focused on germline, heritable genetic modification. Thus, it does not include somatic cell/gene therapy applications.
Poll #GeneEditSummit: a moratorium on human genetic modification? Read More »
The Summit on Human Gene Editing got off to a great start yesterday. I have four posts summarizing all the talks and my impressions on the points made (here, here, here, and here). What was the overall gestalt including from talking to people informally? What were the big takeaway messages so far from Day 1? Diverse views.
Human Gene Editing takeaways from day 1 of #GeneEditSummit Read More »
This is post #4 of my live blogging of the #GeneEditSummit today. It is focused on societal implications so I’m really looking forward to it. You can read posts 1-3, here, here, and here summarizing the talks and key points from the meeting so far. Annelien L. Bredenoord, University Medical Center Utrecht, chaired the session. John Harris,
Live Blogging #GeneEditSummit Day 1 Post #4: Societal Implications of human gene editing Read More »